Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hemopatch is a ready-to-use, absorbable collagen pad designed as a surgical hemostatic device and sealant. It consists of a soft, thin, flexible pad made from bovine-derived collagen coated with N-hydroxysuccinimide functionalized polyethylene glycol (NHS-PEG). Upon application to moist tissue during surgery, the NHS-PEG coating rapidly forms covalent bonds with tissue proteins in the presence of wound fluid (such as blood or lymph), creating an adhering hydrogel that seals the surface. Simultaneously, the bovine collagen induces platelet activation and provides a scaffold for fibrin clot formation to achieve hemostasis. The product is fully absorbed by host tissue within 6–8 weeks post-implantation. Hemopatch is indicated for use in controlling mild or moderate bleeding and sealing leaks of body fluids or air when conventional surgical techniques are ineffective or impractical. It can be used across various soft tissues—including cardiovascular, connective tissue, parenchyma, serosa, viscera—and for dura closure in neurosurgery following trauma or excision[1][2][5][6]. Clinical studies have demonstrated its effectiveness in reducing postoperative complications such as leaks and blood loss[5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hemopatch.